ArticleAmerican journal of translational research2021
Evaluation of the treatment efficacy of systemic care combined with thymopentin and 2HRZE/4HR for primary tuberculosis.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Paradoxical development of pleural-based masses in patients with pleural tuberculosis during treatment: a clinical observational study in China.BMC pulmonary medicine · 2022Observational
- Clinical Efficacy of Psychotherapy Combined with Acupoint Herbal Application on Elderly Patients with Pulmonary Tuberculosis: An Exploratory Study.International journal of general medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of systemic care combined with thymopentin and 2HRZE/4HR in the treatment of primary tuberculosis.
methodsThe clinical data of 93 patients with primary tuberculosis were retrospectively collected and divided into two groups based on the intervention method. Group A (n=46) was treated only with 2HRZE/4HR, and group B (n=47) was treated with the 2HRZE/4HR combined with thymopentin. Meanwhile, both groups received systematic care. The lesion absorption rate, sputum conversion rate (SCR), T lymphocyte subpopulation count, immunoglobulin level, lung function index, changes in sputum supernatant levels of cytokines before and after treatment, and the occurrence of adverse reactions were compared.
resultsGroup B exhibited higher complete absorption rate of foci and lower basic absorption rate than group A (
conclusionSystemic care combined with 2HRZE/4HR was effective for treatment of primary tuberculosis, which is beneficial for improving the immunity, SCR, and the inflammatory status, with low incidence of adverse events and a high safety level.
Indexed as
Identifiers
34017453PMC8129341W3163008510What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.